About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Rheumatology Research Group (GRR) is focused on translational research in immunity-mediated inflammatory diseases (IMIDA), mainly in the area of rheumatology. The GRR is a multidisciplinary group made up of clinical specialists, biologists, bioinformaticians and laboratory technicians. The different research lines of the GRR emphasize the use of high-performance technologies for the study at the cellular and molecular level of the immununopathology of IMIDA, mainly chronic inflammatory arthritis and autoimmune systemic diseases.
At the clinical level, we have developed lines of research in very diverse areas of rheumatology, including chronic inflammatory arthritis (rheumatoid arthritis, spondyloarthropathies), systemic autoimmune diseases (lupus, myositis, Sjögren's syndrome), the study of musculoskeletal imaging, pediatric rheumatology (juvenile idiopathic arthritis, autoimmune systemic diseases, autoinflammatory syndromes), central sensitization syndromes and the study of bone metabolism. One of the main objectives of the GRR is the coordination of basic and clinical research to accelerate the transfer of knowledge to clinical practice and thus improve the quality of life of patients.
IP: Sara Marsal Barril Collaborators: Alejandro Gomez Gomez, Miriam Izquierdo Sans, Ayudas para facultativos investigadores Funding agency: Fundación Española de Reumatología Funding: 135000 Reference: FER/RECERCA/2021/MARSAL Duration: 14/02/2022 - 13/02/2025
IP: Sara Marsal Barril Collaborators: Antonio Julia Cano, Javier Hoyo Pérez, DECISION ON OPTIMAL COMBINATORIAL THERAPIES IN IMIDS USING SYSTEMS APPROACHES (DOCTIS), DECISION ON OPTIMAL COMBINATORIAL THERAPIES IN IMIDS USING SYSTEMS APPROACHES (DOCTIS), Montse Sender Beleta, Nuria Palau Balaña, Edgar Nuñez Gallardo, Raul Tortosa Mendez, María Alba Erra Duran Funding agency: EUROPEAN COMMISSION Funding: 1079085 Reference: DOCTIS_H2020_SC1-BHC2019 Duration: 01/01/2020 - 31/12/2025
IP: Fco Javier Santos Vicente Collaborators: Beatriz Lobo Alvarez, Silvia Muñoz Caller, Carmen Alonso Cotoner, Natalia Rodriguez Santas, Ana Maria Gonzalez Castro, Development, dIagnostic and prevention of gender-related Somatic and mental COmorbitiEs in IRritable bowel syndrome In Europe (D, Marc Pigrau Pastor, Adoración Nieto Ruiz, Alejandro Henao Paez, Consuelo Cammarota , José Alegre Martin, Jesus Castro Marrero, Marta Ribases Haro, Natalia Llonga Tejedor, Amanda Rodríguez Urrutia Funding agency: EUROPEAN COMMISSION Funding: 1148684.84 Reference: DISCOVERIE_H2020-SC1-BHC2019 Duration: 01/01/2020 - 31/05/2025
IP: Sara Marsal Barril Collaborators: Nuria Palau Balaña, Luis Riera Soler, Estefania Moreno Ruzafa, Mireia Lopez Corbeto, Caracterización de RNA-seq de células individuales de células T CD4 + patológicas en artritis idiopática juvenil oligoarticular Funding agency: Instituto de Salud Carlos III Funding: 208120 Reference: PI19/00225 Duration: 01/01/2020 - 30/06/2024
The new therapeutic strategy aims at maintaining the efficacy of thalidomide while avoiding its main systemic adverse effects.
The event, held as part of World Lupus Day, incorporated the perspective of people living with the disease to address the challenges associated with lupus.
The global biopharmaceutical company UCB has acquired the data and clinical knowledge business of IMIDomics, a spin-off of the Vall d’Hebron Institute of Research (VHIR).
